Robeco Institutional Asset Management B.V. lowered its holdings in Pfizer Inc. (NYSE:PFE) by 1.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,291,752 shares of the biopharmaceutical company’s stock after selling 88,313 shares during the period. Pfizer makes up 1.1% of Robeco Institutional Asset Management B.V.’s portfolio, making the stock its 8th biggest position. Robeco Institutional Asset Management B.V. owned about 0.13% of Pfizer worth $315,880,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the company. Viridian Ria LLC grew its holdings in Pfizer by 0.9% during the 4th quarter. Viridian Ria LLC now owns 30,859 shares of the biopharmaceutical company’s stock valued at $1,327,000 after purchasing an additional 280 shares in the last quarter. M Holdings Securities Inc. grew its holdings in Pfizer by 27.9% during the 1st quarter. M Holdings Securities Inc. now owns 39,851 shares of the biopharmaceutical company’s stock valued at $1,692,000 after purchasing an additional 8,693 shares in the last quarter. Annex Advisory Services LLC grew its holdings in Pfizer by 0.7% during the 2nd quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock valued at $2,243,000 after purchasing an additional 382 shares in the last quarter. Princeton Global Asset Management LLC grew its holdings in Pfizer by 14.7% during the 1st quarter. Princeton Global Asset Management LLC now owns 26,736 shares of the biopharmaceutical company’s stock valued at $1,135,000 after purchasing an additional 3,429 shares in the last quarter. Finally, GYL Financial Synergies LLC grew its holdings in Pfizer by 105.3% during the 1st quarter. GYL Financial Synergies LLC now owns 22,987 shares of the biopharmaceutical company’s stock valued at $976,000 after purchasing an additional 11,788 shares in the last quarter. 71.82% of the stock is owned by institutional investors.
PFE stock traded down $0.25 during mid-day trading on Friday, hitting $38.00. 27,652,919 shares of the company were exchanged, compared to its average volume of 25,745,708. The firm has a market cap of $215.95 billion, a P/E ratio of 12.67, a PEG ratio of 3.08 and a beta of 0.63. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.54 and a quick ratio of 1.27. Pfizer Inc. has a twelve month low of $37.68 and a twelve month high of $46.47. The stock’s fifty day moving average is $42.85.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 27.57%. The company had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the business earned $0.77 EPS. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. On average, equities research analysts expect that Pfizer Inc. will post 2.8 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, August 2nd will be given a $0.36 dividend. The ex-dividend date is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.79%. Pfizer’s payout ratio is currently 48.00%.
In other news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total value of $6,753,882.56. Following the transaction, the executive vice president now directly owns 489,647 shares in the company, valued at approximately $21,588,536.23. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Pfizer Inc purchased 50,000 shares of Pfizer stock in a transaction dated Monday, May 13th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $850,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
A number of research firms recently weighed in on PFE. Credit Suisse Group began coverage on shares of Pfizer in a report on Monday, July 15th. They set a “hold” rating and a $47.00 price target for the company. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, July 29th. Morgan Stanley lowered shares of Pfizer from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $48.00 to $40.00 in a report on Tuesday. Goldman Sachs Group reissued a “buy” rating and set a $49.00 price objective on shares of Pfizer in a report on Monday, June 17th. Finally, Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday. Fifteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and a consensus target price of $46.44.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Further Reading: Percentage Decliners
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.